Navigation Links
STERRAD(R) CYCLESURE(R) Biological Indicator is now 24 Hours, Accelerating Instrument Throughput
Date:1/12/2009

IRVINE, Calif., Jan. 12 /PRNewswire/ -- Advanced Sterilization Products (ASP) is pleased to announce that its STERRAD(R) CYCLESURE(R) Biological Indicator readout time has significantly improved from a 48 hour incubation time to only 24 hours. Now, STERRAD(R) System customers can safely record biological indicator results in 50% less time, speeding up instrument throughput in the sterilization department. The product name is also changing to STERRAD(R) CYCLESURE(R) 24 Biological Indicator to reflect this time-saving improvement.

ASP successfully re-engineered the product after receiving feedback from customers requesting a faster incubation period. A faster incubation period keeps sterilization departments moving efficiently as well as limiting the need to purchase duplicate instrument inventories, which is frequently required when waiting for the results of a 48 hour or more biological indicator readout.

"ASP has been providing healthcare organizations with STERRAD(R) System technology and supplies for almost two decades," says Karen Borg, Worldwide Vice President of Marketing for ASP. "We are committed to continuous product innovation and are passionate about designing and marketing infection prevention solutions like the STERRAD(R) CYCLESURE(R) 24 Biological Indicator that not only meet our customers' needs, but often exceed them."

The STERRAD(R) CYCLESURE(R) 24 Biological Indicator can be used with all of ASP's market-leading, low-temperature hydrogen peroxide gas plasma STERRAD(R) Systems: the STERRAD(R) 100NX(TM) System, STERRAD(R) NX(TM) System, STERRAD(R) 100S System, STERRAD(R) 200 System, as well as the STERRAD(R) 50 System. The STERRAD(R) CYCLESURE(R) 24 Biological Indicator is only validated for use in STERRAD(R) Systems.

For information about STERRAD(R) System products, ASP or ASP's line of infection prevention solutions, visit www
'/>"/>

SOURCE Advanced Sterilization Products
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ASP Launches STERRAD(R) Sterility Guide - Eliminating Paperwork and Ensuring Compliance
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Study questions assumptions about human sensitivity to biological motion
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
8. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
9. Biological markers of prostate cancer shed light on cancer burden faced by African-American men
10. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
11. Biological Link Between BRCA1 and Breast Cancer Detailed
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 1Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 1Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 7Stroke Damage Is Less in Rats Given Opioids 49194 1